Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

The purpose of this study is to evaluate the safety and efficacy of the three-drug combination of tucatinib, trastuzumab, and eribulin in patients with de novo and recurrent unresectable metastatic HER-2/neu positive breast cancer as assessed by ORR, PFS and OS after prior treatment with a taxane, trastuzumab, and T-DM1.

Trial Details

NCT ID
NCT05458674
Phase
PHASE2
Sponsor
Criterium, Inc.
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Tucatinib
  • Eribulin
  • Trastuzumab
Locations (sample)
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Washington D.C., District of Columbia, United States|38.89511,-77.03637
  • Albuquerque, New Mexico, United States|35.08449,-106.65114
  • Issaquah, Washington, United States|47.5301,-122.03262
  • Spokane Valley, Washington, United States|47.67323,-117.23937

Key Eligibility Criteria

  • Histologically confirmed HER2+ breast carcinoma, with HER2+ defined by in situ hybridization (ISH) or fluorescence in situ hybridization (FISH) or …
  • Have received previous treatment with trastuzumab deruxtecan in the metastatic setting or have recurred within 6 months of receiving this treatment…
  • Have measurable or non-measurable disease assessable by RECIST 1.1
  • Be at least 18 years of age at time of consent.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →